Scientists are claiming that they will soon be coming up with an ultra-sensitive test for predicting the status of prostate cancer in men after surgery.
It is expected that the test will help the doctors inform the patients if or not they are likely to develop the cancer again and whether or not they should go for further treatment.
It has been said that the new test is 300 times more effective and reliable than the present tests that scale the levels of PSA or prostate-specific antigen present in the blood.
In this test, males who get their cancerous prostate gland removed after surgery are examined for PSA, level which determines the presence of cancer cells that probably may have extended to the other body parts.
It is known that the current tests are not that effective and that they leave a chance of cancer recurring in 40% of completely treated patients.
This was unveiled by the scientists at Chicago's Northwestern University Feinberg School of Medicine and the University International Institute for Nanotechnology.
According to Co-principal Investigator Dr C. Shad Thaxton, the new VeriSens test makes use of nanoparticle-based technology, which he claims is more accurate.
He added that the test will make it possible for the doctors to detect early and inform accurately, so that the patients are given a better chance of survival.